GENFIT announced its 2025 financial results with €65.4 million in revenue, driven by strong sales of Iqirvo® for Primary Biliary Cholangitis (PBC) and milestone payments from partner Ipsen. The company ended the year with €101.1 million in cash, securing a financial runway beyond 2028. Key upcoming milestones include Phase 1b oncology data mid-2026, Phase 2 trials for Acute-on-Chronic Liver Failure (ACLF) and cholangiocarcinoma (CCA) in late 2026, and ongoing development in Primary Sclerosing Cholangitis (PSC). GENFIT is also advancing its diagnostic technology for Metabolic dysfunction-associated steatohepatitis (MASH) with expected sales acceleration and reimbursement progress in 2026.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Alpaca, a brokerage infrastructure startup, secured $435 million in funding to enter prime brokerage services, challenging traditional Wall Street firms. The company’s API supports 94% of US equities and powers tokenized stocks for Kraken. Alpaca’s t...
Raymond James Financial's rating was raised to "Buy" after positive investor event disclosures and a promising preview of its upcoming quarterly results. The company is expected to exceed earnings per share consensus for Q3 FY26, driven by strong per...
Bitcoin and Ethereum experienced combined outflows exceeding $59 million as traders moved funds into stablecoins like USDT and fiat currencies, signaling a cautious stance in the crypto market. This rotation reflects a short-term defensive strategy, ...
Whales have accumulated 70 million XRP over the past week, showing strong confidence despite XRP's price consolidating below resistance levels. The XRP Ledger surpassed 8 million activated accounts, indicating growing network adoption across payments...
